News Release

Capital BlueCross Selects SOLVD Health to Provide Pharmacogenomics Testing for Its Members

SOLVD Health’s LifeKit® PreScript is a genetic test that identifies which medications are most likely to be effective based on an individual’s DNA.

CARLSBAD, Calif., April 6, 2021 – SOLVD Health, a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, today announced a collaboration with Capital BlueCross that gives network providers and their patients access to state-of-the-art pharmacogenomics (PGx) testing, which can help make medication selection safer and more effective.

As of April 1, Capital BlueCross providers and patients now have covered access to SOLVD Health’s LifeKit® PreScript, a genetic test that helps providers, based on their patient’s DNA, identify which medications are most likely to be effective and which should be avoided.

“No medicine works the same for everyone,” said Keri Donaldson, MD, CEO of SOLVD Health. “Results can vary widely because a person’s genetics impact how their body metabolizes different medications. Instead of going through the painstaking process of trial and error, which can be expensive, time-consuming, and frustrating, LifeKit PreScript can help providers select medications most likely to be effective from the start.”

“To our knowledge, no other molecular diagnostics company has received more than one Breakthrough Device designation, so having it for both our tests has always been remarkable,” said Keri Donaldson, CEO of SOLVD Health. “This new MCIT rule provides yet another important benefit, which will dramatically accelerate our commercialization path so we can provide these tests to those who need it most sooner.”

Using a simple cheek swab sample, LifeKit PreScript analyzes 14 genetic variants that impact how a person’s body metabolizes medication. Providers receive a detailed report that indicates how an individual will respond to the medications they are currently prescribed, as well as any medications being considered for future use, to help support more informed decision-making about drug selection.

Over 5 billion prescriptions are filled each year1, but response rates for many drugs are only 50-75%2. It is estimated that non-optimized medications produce an additional $528 billion in healthcare costs each year.3

Research has shown that >90% of patients possess clinically actionable genetic variants that affect their drug response.4,5 One study showed that on average, patients with mood/anxiety disorders using PGx testing have a ~$2,000 reduction in health care costs, 40% reduction in ER visits, and a 60% reduction in hospitalizations.6 In a separate study, individuals who received PGx-guided decision support tools therapy were 1.71 times more likely to achieve symptom remission relative to individuals who received treatment as usual.7

1IMS Institute for Healthcare Informatics
2Spear BB, Heath-Chiozzi M, Hu J: Clinical application of pharmacogenetics. Trends Mol. Med.7, 201–204 (2001).
3Watanabe, J. H., et al. Cost of Prescription Drug–Related Morbidity and Mortality. Annals of Pharmacotherapy. 2018; 52(9), 829–837.
4Van Driest, SL, et. al., Clin Pharmacol Ther. 2014; 95(4): 423–431.
5Yuan, J. et. al., Jmol Diag. 2016; 18(3): 438-445.
6Perlis et al. Pharmacogenetic Testing Among Patients With Mood and Anxiety Disorders Is Associated With Decreased Utilization and Cost: A Propensity-Score Matched Study. Depression and Anxiety. 2018; 35(10), 946–952.
7Bousman et al. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials; Dec 2018

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, we are enabling individuals and their providers to make better decisions about their health and the health of their families. We accomplish this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about us, our solutions, and our career opportunities, visit us at

Media Contact:
Public Relations;